149 related articles for article (PubMed ID: 32769410)
1. Proton pump inhibitors reduce phlebotomy burden in patients with HFE-related hemochromatosis: a systematic review and meta-analysis.
Dirweesh A; Anugwom CM; Li Y; Vaughn BP; Lake J
Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1327-1331. PubMed ID: 32769410
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis: Double-Blind Randomized Placebo-Controlled Trial.
Vanclooster A; van Deursen C; Jaspers R; Cassiman D; Koek G
Gastroenterology; 2017 Sep; 153(3):678-680.e2. PubMed ID: 28624580
[TBL] [Abstract][Full Text] [Related]
3. Proton Pump Inhibitors Reduce the Frequency of Phlebotomy in Patients With Hereditary Hemochromatosis.
van Aerts RM; van Deursen CT; Koek GH
Clin Gastroenterol Hepatol; 2016 Jan; 14(1):147-52. PubMed ID: 26240005
[TBL] [Abstract][Full Text] [Related]
4. The modified iron avidity index: a promising phenotypic predictor in HFE-related haemochromatosis.
Verhaegh PL; Moris W; Koek GH; van Deursen CT
Liver Int; 2016 Oct; 36(10):1535-9. PubMed ID: 26992127
[TBL] [Abstract][Full Text] [Related]
5. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
Kowdley KV; Modi NB; Peltekian K; Vierling JM; Ferris C; Valone FH; Gupta S
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1118-1128. PubMed ID: 37863080
[TBL] [Abstract][Full Text] [Related]
6. GNPAT variant (D519G) is not associated with an elevated serum ferritin or iron removed by phlebotomy in patients referred for C282Y-linked hemochromatosis.
Levstik A; Stuart A; Adams PC
Ann Hepatol; 2016 Nov-Dec 2016; 15(6):907-910. PubMed ID: 27740525
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Transient elevation of serum ferritin in a Sri Lankan with homozygosity for H63D mutation in the HFE gene: a case report.
Wickramasinghe W; Karunathilaka C; Jayasinghe S; Gooneratne L
J Med Case Rep; 2020 Jul; 14(1):93. PubMed ID: 32641120
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis.
Hutchinson C; Geissler CA; Powell JJ; Bomford A
Gut; 2007 Sep; 56(9):1291-5. PubMed ID: 17344278
[TBL] [Abstract][Full Text] [Related]
10. [Non-HFE hemochromatosis: a case report].
Martínez-Ávila MC; Toro-Trujillo E; Alvarez-Londoño A
Rev Gastroenterol Peru; 2021; 41(4):261-264. PubMed ID: 35613398
[TBL] [Abstract][Full Text] [Related]
11. Effect of Native American ancestry on iron-related phenotypes of Alabama hemochromatosis probands with HFE C282Y homozygosity.
Barton JC; Barton EH; Acton RT
BMC Med Genet; 2006 Mar; 7():22. PubMed ID: 16533407
[TBL] [Abstract][Full Text] [Related]
12. Hereditary hemochromatosis: missed diagnosis or misdiagnosis?
Cherfane CE; Hollenbeck RD; Go J; Brown KE
Am J Med; 2013 Nov; 126(11):1010-5. PubMed ID: 24054178
[TBL] [Abstract][Full Text] [Related]
13. Do pregnancies reduce iron overload in HFE hemochromatosis women? results from an observational prospective study.
Scotet V; Saliou P; Uguen M; L'Hostis C; Merour MC; Triponey C; Chanu B; Nousbaum JB; Le Gac G; Ferec C
BMC Pregnancy Childbirth; 2018 Feb; 18(1):53. PubMed ID: 29454332
[TBL] [Abstract][Full Text] [Related]
14. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis.
Hicken BL; Tucker DC; Barton JC
Am J Gastroenterol; 2003 Sep; 98(9):2072-7. PubMed ID: 14499790
[TBL] [Abstract][Full Text] [Related]
15. Interventions for hereditary haemochromatosis: an attempted network meta-analysis.
Buzzetti E; Kalafateli M; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011647. PubMed ID: 28273330
[TBL] [Abstract][Full Text] [Related]
16. [Hereditary hemochromatosis].
Dantas W
Rev Gastroenterol Peru; 2001; 21(1):42-55. PubMed ID: 12170286
[TBL] [Abstract][Full Text] [Related]
17. Cirrhosis in Hemochromatosis: Independent Risk Factors in 368 HFE p.C282Y Homozygotes.
Barton JC; McLaren CE; Chen WP; Ramm GA; Anderson GJ; Powell LW; Subramaniam VN; Adams PC; Phatak PD; Gurrin LC; Phillips JD; Parker CJ; Emond MJ; McLaren GD
Ann Hepatol; 2018 Aug; 17(5):871-879. PubMed ID: 30145563
[TBL] [Abstract][Full Text] [Related]
18. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.
Rombout-Sestrienkova E; Nieman FH; Essers BA; van Noord PA; Janssen MC; van Deursen CT; Bos LP; Rombout F; van den Braak R; de Leeuw PW; Koek GH
Transfusion; 2012 Mar; 52(3):470-7. PubMed ID: 21848963
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of hereditary hemochromatosis.
Salgia RJ; Brown K
Clin Liver Dis; 2015 Feb; 19(1):187-98. PubMed ID: 25454304
[TBL] [Abstract][Full Text] [Related]
20. Examining the clinical use of hemochromatosis genetic testing.
Lanktree MB; Lanktree BB; Paré G; Waye JS; Sadikovic B; Crowther MA
Can J Gastroenterol Hepatol; 2015; 29(1):41-5. PubMed ID: 25706573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
